Cypress Bioscience Inc. to Present at Oppenheimer 21st Annual Healthcare Conference
Published: Nov 03, 2010
SAN DIEGO, CA--(Marketwire - November 03, 2010) - Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced that Sabrina Martucci Johnson, its Chief Operating Officer and Chief Financial Officer, will present at Oppenheimer's 21st Annual Healthcare Conference today, November 3, 2010.
The Oppenheimer conference is being held at the Waldorf=Astoria Hotel in New York, NY. Ms. Johnson is scheduled to present on Wednesday, November 3rd at 10:15 am Eastern Time. The audio broadcast of this presentation can be accessed at http://www.veracast.com/webcasts/opco/healthcare2010/44204459.cfm.
A replay of the presentation will be available at the same web address as well as on Cypress' website, http://www.cypressbio.com/events.php.
About Cypress Bioscience
Cypress Bioscience is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system. Since 1999, Cypress has received FDA approvals for both of the products it brought to the FDA during that period, including for Prosorba™, a medical device for rheumatoid arthritis, and Savella® (milnacipran HCl), for fibromyalgia. The Company focuses on generating stockholder value by reaching clinical development milestones as quickly and efficiently as possible. Cypress' development-stage assets include CYP-1020 for cognitive impairment in schizophrenia, Staccato® nicotine for smoking cessation and intranasal carbetocin for autism. More information on Cypress and its products and development assets is available at http://www.cypressbio.com/.
For more information about Cypress, please visit the Company's website at www.cypressbio.com.
For additional information please contact
Investor Relations Manager